173 related articles for article (PubMed ID: 35878018)
1. Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population.
Mecoli CA; Igusa T; Chen M; Wang X; Albayda J; Paik JJ; Tiniakou E; Adler B; Richardson C; Kelly W; Danoff S; Mammen AL; Platz EA; Rosen A; Christopher-Stine L; Casciola-Rosen L; Shah AA
Arthritis Rheumatol; 2023 Apr; 75(4):620-629. PubMed ID: 35878018
[TBL] [Abstract][Full Text] [Related]
2. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
3. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
4. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
5. Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy.
Izuka S; Komai T; Shoda H; Fujio K
Rheumatol Int; 2023 Feb; 43(2):335-343. PubMed ID: 36175662
[TBL] [Abstract][Full Text] [Related]
6. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
[TBL] [Abstract][Full Text] [Related]
7. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Yield of Computed Tomography for Cancer Detection in a Tertiary Referral Population of Idiopathic Inflammatory Myositis Patients.
Mecoli CA; Chee B; Chen M; Wang X; Albayda J; Paik JJ; Tiniakou E; Adler B; Kelly W; Mammen AL; Platz EA; Casciola-Rosen L; Christopher-Stine L; Shah AA
Arthritis Care Res (Hoboken); 2023 Oct; 75(10):2142-2150. PubMed ID: 36913182
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
10. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
[TBL] [Abstract][Full Text] [Related]
11. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
12. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
13. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
[TBL] [Abstract][Full Text] [Related]
14. Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort.
Loganathan A; Gupta L; Rudge A; Lu H; Bowler E; McMorrow F; Naveen R; Anuja AK; Agarwal V; McHugh N; Tansley S
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38479813
[TBL] [Abstract][Full Text] [Related]
15. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
Teel A; Lu J; Park J; Singh N; Basharat P
Semin Arthritis Rheum; 2022 Dec; 57():152088. PubMed ID: 36116345
[TBL] [Abstract][Full Text] [Related]
16. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry.
Gupta L; Nune A; Naveen R; Verma R; Prasad P; Kharbanda R; Rathore U; Rai MK; Singh MK; Anuja AK; Agarwal V
Rheumatol Int; 2022 Jul; 42(7):1143-1154. PubMed ID: 35031847
[TBL] [Abstract][Full Text] [Related]
18. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
[TBL] [Abstract][Full Text] [Related]
19. Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease.
Szczesny P; Barsotti S; Nennesmo I; Danielsson O; Dastmalchi M
Front Immunol; 2022; 13():866701. PubMed ID: 35603214
[TBL] [Abstract][Full Text] [Related]
20. A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies.
Tampoia M; Notarnicola A; Abbracciavento L; Fontana A; Giannini M; Louis Humbel R; Iannone F
J Clin Lab Anal; 2016 Nov; 30(6):859-866. PubMed ID: 27074881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
